Lynk Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Trial of LNK01004 Ointment for Vitiligo

Phase 2LNK01004 OintmentPositive

AI Analysis

Summary

Lynk Pharmaceuticals announced the first patient dosed in a Phase II clinical trial of LNK01004 Ointment for vitiligo treatment. The company is a clinical-stage innovator focused on immune and inflammatory diseases.

Clinical Trial Data

Phase

Phase II

Outcome Details

First patient dosed

Importance:5/10

Sentiment:

0.50

clinical-trialphase-2vitiligoimmunologydermatology

Related Companies

$HGZDY $CHHE $TRAX

Read the original article

Published by PR Newswire Clinical Trials on July 9, 2026 12:00 AM

Read Original